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M. setense is an emerging organ-
ism of the M. fortuitum group that must 
be added to the growing list of rapidly 
growing mycobacteria isolated from 
humans. The initial gram-positive rod 
appearance of M. setense may delay its 
accurate identifi cation. Determination 
of antimicrobial drug susceptibility 
needs to be conducted by the reference 
broth dilution method. Further reports 
are warranted to characterize the role 
of M. setense in infection.
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To the Editor: We read with great 
interest the recent report by Longtin 
and colleagues (1) describing human 
bocavirus (HBoV) infection among 
Canadian children with acute respi-
ratory tract illnesses (ARI). The au-
thors identifi ed HBoV by PCR in na-
sopharyngeal aspirates from 13.8% of 
young children hospitalized with ARI, 
an infection rate well within the range 
reported by other studies on children 
(2). However, these authors also de-
tected an unexpectedly high rate of 
HBoV for their control group (43%), 
>3 times the rate for ARI case-patients. 
In contrast, several similar studies did 
not detect HBoV in asymptomatic chil-
dren. Kesebir et al. detected HBoV in 
23 (5.2%) of 425 young children with 
ARI but in none of 96 children during 
routine well-child visits (3). Maggi 
et al. detected HBoV in 9 (4.5%) of 
200 infants with ARI but in none of 
30 healthy infants or 21 preadolescent 
healthy children without signs of ARI 
or history of asthma or wheezing (4). 
Finally, Allander et al. detected HBoV 
in 5 (19%) of 259 young children with 
acute expiratory wheezing but in none 
of 64 children who had not had respi-
ratory symptoms during the preceding 
4 weeks (5). In a recent study, we de-
tected HBoV by PCR in 44 (12%) of 
369 Thai children <4 years of age hos-
pitalized with pneumonia but in only 
2 (2%) of 85 asymptomatic age and 
temporally matched controls (6).
The inexplicably high rate of 
HBoV infection for patient controls 
reported by Longtin et al. (1) may re-
fl ect a unique feature of the children 
selected. The 100 controls were chil-
dren without concomitant respiratory 
symptoms or fever at admission who 
were hospitalized during the study pe-
riod for elective surgery, primarily of 
the ear, nose, and throat (71%). Most 
surgeries consisted of myringotomies, 
adenoidectomies, and tonsillectomies. 
The authors reported that these surger-
ies were more frequently performed 
on children found to be PCR positive 
for HBoV than on children negative 
for HBoV (84% vs. 61%). One possi-
ble explanation is that HBoV infection 
may directly induce infl ammation of 
tonsillar tissues or facilitate bacterial 
superinfection prompting surgical in-
tervention. Another possibility is that 
infl ammation of mucosal lymphoid 
tissues enhances HBoV replication by 
recruitment of immune cells permis-
sive for HBoV infection or by latent 
virus reactivation. Persistent infections 
and dependence on rapidly dividing 
cells are common features of the relat-
ed parvoviruses, for example, human 
erythrovirus B19 (7). The presence of 
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low-level persistent HBoV infections 
may also help explain the exception-
ally high rates of respiratory viral co-
infections found with HBoV, as high 
as 90% in 1 study (average 42%) (2,6). 
Longtin et al. (1) found that 71% of 
the HBoV-positive patients were also 
co-infected with another respiratory 
virus. As we previously hypothesized 
(6), co-virus–induced cellular damage 
resulting in high levels of cellular divi-
sion and differentiation may stimulate 
HBoV reactivation and replication, 
as has been shown for polyomavirus 
following induced kidney damage in 
newborn mice (8).
To assess whether HBoV is pres-
ent in tonsillar lymphocytes and there-
fore possibly explain the high rate of 
PCR positives obtained by Longtin 
et al. (1) in their patient controls, we 
tested DNA extracts of lymphocytes 
separated by Ficoll-Paque from na-
sopharyngeal tonsils or adenoids (AL) 
and palatine/lingual tonsils (TL) from 
164 patients (mostly children) under-
going routine adenoidectomies and 
tonsillectomies for HBoV DNA. Of 
these children, 21 had AL only, 57 had 
TL only, 18 had both AL and TL col-
lected separately, and 68 had AL and 
TL combined in 1 container. Hyper-
tropic tonsil and adenoid tissues were 
removed because of clinical complica-
tions, generally obstructive sleep ap-
nea, otitis media, or chronic tonsillitis. 
Data were not available on whether 
the children had concurrent respiratory 
tract illness, although surgeries would 
likely be postponed if symptoms were 
apparent. The median age of 162 chil-
dren for whom age data were avail-
able was 5 years (range 1–19.7 years). 
HBoV real-time PCRs were performed 
as previously described, targeting 2 
unique regions of the HBoV genome 
(9). All extractions were performed in 
a separate laboratory from PCR activi-
ties, and negative-assay controls were 
included in all PCR runs to monitor 
for DNA contamination.
HBoV DNA was detected by 
both PCRs in lymphocytes from 53 
(32.3%) children (median age 3.7 
years, range 1–7.6 years). A single 
assay target (nonstructural protein 
gene NS1 or NP-1) was positive in 
specimens from 6 additional children 
(3.7%), but these specimens were 
classifi ed as HBoV negative because 
they did not meet our strict criteria for 
a positive test result. Children PCR 
negative for HBoV were signifi cantly 
older (median age 5.5 years, range 
1.8–19.7 years; p<0.001). HBoV was 
more often detected in AL (56%) than 
TL specimens (16%; p<0.001); the 
age distributions for children from 
each group were similar. Among 12 
HBoV-positive children from whom 
both AL and TL were available and 
collected in separate containers, 6 
were positive for HBoV in both spec-
imens, 4 were positive for AL alone, 
and 2 were positive for AL but only 
for a single PCR assay target. More-
over, HBoV was present at a substan-
tially higher load in AL (median 3.1 
× 105 copies/107 cells; range 2.8 × 101 
to 1.2 × 109 copies/107 cells) than TL 
(median 1.6 × 103 copies/107 cells; 
range 0.1 × 100 to 5.3 x107 copies/107 
cells) as measured by quantitative 
PCR (9). We have no clear explana-
tion for the relative predominance 
of HBoV DNA in AL. The adenoids 
are located at the back of the na-
sopharnyx in close proximity to in-
haled pathogens and are covered with 
ciliated pseudostratifi ed epithelium 
(respiratory epithelium) that may bet-
ter support primary virus replication 
than the palantine and lingual tonsils, 
which are located in the lower phar-
ynx and covered with nonkeratinized, 
stratifi ed, squamous epithelium.
Our fi ndings suggest that HBoV 
may establish latent or persistent in-
fections of mucosal lymphocytes or 
contribute to tonsillar hyperplasia in 
young children. Further studies with 
appropriately matched controls will 
be necessary to fully understand the 
nature of HBoV infection and its role 
in human disease.
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Assessment of 
Reporting Bias for 
Clostridium diffi cile 
Hospitalizations, 
United States 
To the Editor: Burckhardt et al. 
(1) recently reported on Clostridium 
diffi cile–associated disease (CDAD) 
in Saxony, Germany. In contrast to the 
observation by Wilcox and Fawley in 
the United Kingdom (2), the report 
from Germany argued against a re-
porting bias for gastroenteritides as a 
cause of the observed increase in the 
incidence of CDAD diagnoses from 
2002 through 2006. To explore this 
issue further, I examined the potential 
infl uence of such reporting bias on 
the observed increase in the incidence 
of hospitalizations of patients with 
CDAD in the United States from 2000 
through 2005.
In the 2000–2005 data from the 
National Inpatient Sample data from 
the Agency for Healthcare Research 
and Quality (3,4), I identifi ed hospital-
izations for gastrointestinal infections 
caused by C. diffi cile, Salmonella, ro-
tavirus, and other unspecifi ed infec-
tious agents, using the corresponding 
diagnosis codes from the International 
Classifi cation of Diseases, 9th Revi-
sion, Clinical Modifi cation. I obtained 
censal and intercensal data on the num-
bers of the U.S. population from 2000 
through 2005 from the U.S. Census 
Bureau (5). Based on these records, 
I calculated hospitalization incidence 
for each of the infectious causes.
Annual incidence of CDAD in-
creased from 49.2 to 101.6 per 100,000 
population within the period examined. 
Within the same time frame, the inci-
dence of CDAD as the principal diag-
nosis also more than doubled, increas-
ing from 11.6 to 25.8 hospitalizations 
per 100,000. Although the incidence of 
hospitalizations for Salmonella infec-
tions per 100,000 population remained 
stable, rotavirus infection showed a 
slight increase (from 10.8 to 14.5) as 
did other infectious gastroenteritides 
(from 38.9 to 49.9/100,000) (Figure). 
Thus, although a slight increase in 
the incidence was exhibited, a report-
ing bias for gastroenteric infections 
with organisms other than C. diffi cile 
does not appear to account fully for 
the observed doubling of the over-
all incidence of hospitalizations with 
CDAD in the United States from 2000 
through 2005.
 Marya D. Zilberberg*†
*University of Massachusetts, Amherst, 
Massachusetts, USA; and †EviMed Re-




  1.  Burckhardt F, Friedrich A, Beier D, Eck-
manns T. Clostridium diffi cile surveillance 
trends, Saxony, Germany. Emerg Infect 
Dis. 2008;14:691–2.
  2.  Wilcox M, Fawley W. Viral gastroenteritis 
increases the reports of Clostridium diffi cile 
infection. J Hosp Infect. 2007;66:395–6. 
DOI: 10.1016/j.jhin.2007.05.010
  3.  Agency for Healthcare Research and Qual-
ity. Nationwide Inpatient Sample (NIS). 
Healthcare Cost and Utilization Project 
[cited 2008 Apr 1]. Available from http://
www.hcup-us.ahrq.gov/nisoverview.jsp
  4.  Agency for Healthcare Research and 
Quality. HCUPnet. Healthcare Cost and 
Utilization Project (HCUP). 2000–2004 
[cited 2008 Apr 1]. Available from http://
hcupnet.ahrq.gov
  5.  US Census Bureau [cited 2008 Apr 1] 
Available from http://www.census.gov 
Address for correspondence: Marya Zilberberg, 
EviMed Research Group, LLC, PO Box 303, 
Goshen, MA 01032, USA; email: marya@
evimedgroup.org
1334 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 8, August 2008
Figure. Annual incidence per 100,000 population of all hospitalizations for Clostridium 
diffi cile–associated disease (CDAD) compared with hospitalizations for a primary diagnosis 
of CDAD and with gastroenteritides caused by Salmonella, rotavirus, and other unspecifi ed 
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